Altimmune (ALT) Corporate presentation summary

Mission and leadership

• Aims to revolutionize care for serious liver diseases, focusing on innovative therapies.

• Leadership team includes experienced executives in clinical, commercial, financial, and scientific roles.

Lead candidate and pipeline

• Lead asset pemvidutide is a dual glucagon/GLP-1 receptor agonist with balanced 1:1 activity.

• Pipeline targets metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

• Robust patent portfolio extends into the 2040s.

Clinical data and efficacy

• Phase 2b MASH trial showed rapid, significant reductions in liver fat, inflammation, and fibrosis markers at 24 and 48 weeks.

• 1.8 mg dose maintained >50% liver fat reduction and 7.5% weight loss at 48 weeks, with no plateau.

• Significant improvements in non-invasive fibrosis markers (ELF, LSM, cT1) and ALT levels.

• Favorable tolerability profile with low discontinuation rates and most GI adverse events occurring early and mild to moderate.